Alcohol Clinical Trials in Nashville, Tennessee
8 recruitingNashville, Tennessee
Showing 1–8 of 8 trials
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
89bio, Inc.762 enrolled296 locationsNCT06419374
Recruiting
Phase 3
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
89bio, Inc.1,350 enrolled342 locationsNCT06318169
Recruiting
Phase 2
GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV
Cardiovascular Disease PreventionSmoking, CigaretteHIV+1 more
Vanderbilt University Medical Center200 enrolled1 locationNCT07221214
Recruiting
Phase 3
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
MASH - Metabolic Dysfunction-Associated SteatohepatitisNASH - Nonalcoholic Steatohepatitis
Akero Therapeutics, Inc2,150 enrolled318 locationsNCT06528314
Recruiting
Not Applicable
Combining a Smartphone App With Medications to Manage Heavy Drinking
Alcohol Use Disorder (AUD)
VA Office of Research and Development330 enrolled15 locationsNCT06303778
Recruiting
Early Phase 1
The Gut, Liver And Metabolome in Human Immunodeficiency Virus and Non Alcoholic Fatty Liver Disease
Non-Alcoholic Fatty Liver DiseaseHIVMetabolic-Associated Steatotic Liver Disease
Vanderbilt University Medical Center63 enrolled1 locationNCT06113003
Recruiting
Phase 2
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
Cardiovascular DiseasesHIV InfectionsDysbiosis+2 more
Vanderbilt University Medical Center250 enrolled1 locationNCT05288790
Recruiting
Phase 2
FXR Effect on Severe Alcohol-Associated Hepatitis (FRESH) Study
Alcohol Associated Hepatitis
Intercept Pharmaceuticals80 enrolled31 locationsNCT05639543